Glymphatic-Circadian Axis Enhancement Therapy for Parkinson's Disease
Background and Rationale
This Phase 1b/2a clinical trial targets the emerging connection between glymphatic system dysfunction and circadian rhythm disruption in Parkinson's disease pathogenesis. The glymphatic system, responsible for brain waste clearance including α-synuclein aggregates, operates primarily during sleep and is regulated by circadian mechanisms. In Parkinson's disease, both glymphatic dysfunction and circadian disruption occur early and may perpetuate neurodegeneration through impaired protein clearance and neuroinflammation. The intervention combines sleep optimization strategies, circadian rhythm stabilization through light therapy and melatonin, and pharmacological enhancement of glymphatic flow using noradrenergic modulators. Advanced neuroimaging techniques including diffusion tensor imaging along perivascular spaces (DTI-ALPS) and dynamic contrast-enhanced MRI assess glymphatic function, while polysomnography and actigraphy monitor sleep architecture and circadian patterns. This approach represents a paradigm shift toward addressing fundamental clearance mechanisms rather than symptomatic treatment alone.
This experiment directly tests predictions arising from the following hypotheses:
- Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation
- Circadian Glymphatic Rescue Therapy (Melatonin-focused)
- SASP-Driven Aquaporin-4 Dysregulation
- Glymphatic System-Enhanced Antibody Clearance Reversal
- Aquaporin-4 Polarization Rescue
Experimental Protocol
Phase 1: Screening and Baseline Assessment (Days -28 to -1)• Screen 120 early-stage Parkinson's patients (Hoehn-Yahr stages 1-2.5) aged 45-75 years
• Conduct comprehensive neurological evaluation including MDS-UPDRS Parts I-IV
• Perform baseline glymphatic function assessment via diffusion tensor imaging along perivascular spaces (DTI-ALPS)
• Establish circadian rhythm profiles using 14-day actigraphy and salivary melatonin sampling
• Obtain baseline CSF biomarkers (α-synuclein, tau, Aβ42) via lumbar puncture
• Conduct sleep polysomnography and cognitive assessment battery (MoCA, detailed neuropsych testing)
Phase 2: Randomization and Treatment Initiation (Days 0-7)
• Randomize 80 eligible participants to four arms (n=20 each): combination therapy, glymphatic enhancement only, circadian therapy only, placebo
• Glymphatic enhancement: Transcranial focused ultrasound (tFUS) 3x/week targeting perivascular spaces
• Circadian therapy: Bright light therapy (10,000 lux, 30 min morning) + evening melatonin (3mg)
• Combination: Both interventions with optimized timing
• Initiate 24-hour safety monitoring for first week
Phase 3: Active Treatment Period (Weeks 2-12)
• Continue assigned interventions with weekly safety assessments
• Perform monthly MDS-UPDRS evaluations and actigraphy monitoring
• Conduct DTI-ALPS imaging at weeks 4, 8, and 12
• Collect CSF samples at weeks 6 and 12 for biomarker analysis
• Monitor medication requirements and adjust as clinically indicated
Phase 4: Follow-up Assessment (Weeks 13-24)
• Reduce intervention frequency by 50% (weeks 13-16)
• Complete cessation of interventions (weeks 17-24)
• Perform comprehensive outcome assessments at weeks 16, 20, and 24
• Collect final CSF sample and neuroimaging at week 24
• Document any sustained benefits or rebound effects
Expected Outcomes
Glymphatic Function Improvement: 25-35% increase in DTI-ALPS index in combination therapy group compared to placebo (effect size d=0.8-1.2)
Motor Symptom Amelioration: 8-12 point reduction in MDS-UPDRS Part III scores in active treatment groups vs 2-point reduction in placebo (p<0.01)
CSF Biomarker Changes: 15-25% reduction in pathological α-synuclein species and 20-30% decrease in total tau levels in combination group
Circadian Rhythm Normalization: Restoration of melatonin rhythm amplitude (>50% increase in peak-to-trough ratio) and actigraphy-measured sleep efficiency improvement (>10%)
Cognitive Benefits: 2-4 point improvement in MoCA scores and 15-25% enhancement in executive function tasks in combination therapy group
Safety Profile: <10% serious adverse event rate across all groups, with no treatment-related serious neurological complicationsSuccess Criteria
•
Primary Efficacy Endpoint: Combination therapy demonstrates statistically significant improvement (p<0.025, Bonferroni-corrected) in composite glymphatic-motor score vs placebo
•
Biomarker Validation: ≥20% improvement in DTI-ALPS index with corresponding ≥15% reduction in CSF α-synuclein in combination group (correlation r>0.4, p<0.05)
•
Clinical Meaningfulness: MDS-UPDRS Part III improvement meets minimal clinically important difference (≥5.2 points) in ≥60% of combination therapy participants
•
Safety Threshold: Maintain serious adverse event rate <15% across all treatment arms with no treatment-related deaths or permanent neurological deficits
•
Mechanistic Evidence: Demonstrate dose-response relationship between glymphatic enhancement and biomarker clearance (linear trend p<0.05)
•
Sustained Benefits: ≥50% of responders maintain clinical improvement at 12-week post-treatment follow-up with effect size ≥0.5 vs placebo